| Metric | Value ($ M) | Q1 FY26 |
|---|---|---|
| Revenue | 105.4K | 7.7% |
| Total Income | 105.4K | 7.7% |
| Expenditure | 104.1K | 7.5% |
| PBT | 1.3K | 24.4% |
| Net Profit | 614.00 | 21.7% |
| OPM | 1.25% | 0.19pp |
| NPM | 0.58% | 0.22pp |
| EPS | 5.17 | 17.7% |
McKesson Reports Q1 FY27 Results and Raises Full Year Adjusted EPS Guidance
06 Aug 2026 · 6 Aug, 1:44 am
Summary
McKesson Corporation reported strong first quarter results for fiscal year 2027, with consolidated revenues increasing by 8% to $105.4 billion. Adjusted Earnings per Diluted Share saw a significant 20% increase to $9.93, driven by strong operational growth. The company also raised its full-year Adjusted EPS guidance to $44.20-$45.00, reflecting confidence in sustainable operational momentum. Management highlighted disciplined execution and enterprise-wide momentum as key drivers for the positive start to the fiscal year.
Key Highlights
- 1
Consolidated revenues for the first quarter of fiscal year 2027 reached $105.4 billion, an increase of 8% compared to the prior year.
- 2
Adjusted Earnings per Diluted Share for the first quarter increased by 20% to $9.93, up from $8.26 in the prior year.
- 3
McKesson's Board of Directors approved a 15% increase to the quarterly dividend, raising it to $0.94 per share, marking the tenth consecutive year of dividend increases.
- 4
The company returned $2.6 billion to shareholders in the first quarter, including $2.25 billion through an accelerated share repurchase program.
- 5
Full year fiscal 2027 Adjusted Earnings per Diluted Share guidance was raised to a range of $44.20 to $45.00, indicating 13% to 15% growth compared to the prior year.
- 6
The North American Pharmaceutical segment reported revenues of $86.8 billion, a 5% increase year-over-year.
- 7
The Oncology & Multispecialty segment saw revenues grow by 33% to $14.2 billion.
Management Comments
Brian Tyler
McKesson delivered a strong start to fiscal 2027, underscored by momentum across the enterprise and disciplined execution against our strategic priorities. Our first quarter performance exceeded our expectations, highlighted by 20% growth in Adjusted Earnings per Diluted Share. It demonstrates the strength of our core distribution businesses, continued growth in oncology and multispecialty, and solid execution across our biopharma services platform. These results are a testament to the dedication of Team McKesson, whose commitment to excellence continues to drive our success and impact across healthcare. As we look ahead, we remain confident that our strategy and disciplined execution will continue to position McKesson for sustainable long-term growth and value creation.
Kenny Cheung
The raise in full year Adjusted Earnings per Diluted Share outlook reflects strong first quarter performance and sustainable operational momentum. Our confidence in the business is supported by durability across the enterprise and our commitment to disciplined capital allocation.
Informational and educational content only. Not investment advice.